Pelacarsen Trial Fails to Cut Cardiovascular Risk Despite 80% Lp(a) Reduction
Novartis and Ionis Pharmaceuticals said their experimental drug pelacarsen did not reduce the risk of heart attack or stroke in a Phase 3 trial. The drug lowered patients’ Lp(a) levels by 80%, but the reduction did not translate into a statistically significant improvement in the trial’s composite cardiovascular endpoint. Full results are scheduled for presentation at the American Heart Association’s annual meeting on Saturday in Chicago.
Why it matters
The result weakens the investment case that lowering genetically driven Lp(a) alone will prevent cardiovascular events and raises uncertainty for other companies developing Lp(a)-targeting medicines. Novartis shares fell 16% after the announcement, while detailed trial data could clarify whether the outcome reflects the drug, the study design or other treatment factors.
Key facts
- 1Pelacarsen reduced Lp(a) blood levels by 80% but failed to lower heart attack and stroke risk in the trial. medscape.com
- 2Novartis said the Phase 3 study missed its primary endpoint, which combined death, heart attack, stroke and revascularization procedures. medscape.com
- 3The complete pelacarsen findings are due to be presented Saturday at the AHA scientific meeting in Chicago. medscape.com
- 4Novartis shares dropped 16% after the trial announcement. medscape.com
Open questions
- The materials do not provide the complete trial dataset, including event counts, statistical values or the size of the treatment effect beyond the reported 80% Lp(a) reduction.
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.